Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“First Generics” Will Get Expedited ANDA Reviews Under New FDA Policy

Executive Summary

FDA's "First Generics" policy sets a priority review goal of six months for ANDAs for which there is no marketed generic equivalent

You may also be interested in...



ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office

CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.

GIVE Generics A Break: FDA Review Plan Draws Grumbles From Industry

FDA's announcement about its new review procedures for generic drugs may well be tailored to have more impact on congressional appropriations committees than on the ANDAs themselves

GIVE Generics A Break: FDA Review Plan Draws Grumbles From Industry

FDA's announcement about its new review procedures for generic drugs may well be tailored to have more impact on congressional appropriations committees than on the ANDAs themselves

Related Content

UsernamePublicRestriction

Register

PS047678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel